{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-029846","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.389191+00:00","generated_at":"2026-05-15T09:48:45.575124+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Protalix reports FY2025 results; EC approves Elfabrio E4W regimen triggering $25M milestone","bullets":["EC approved Elfabrio 2mg/kg every-4-weeks dosing for stable adults with Fabry in EU; $25M milestone from Chiesi triggered.","Total 2026 revenue guided to $78M-$83M including milestone; Elfabrio sales $33-35M, Elelyso $20-23M.","Phase 2 RELEASE trial for PRX-115 (uncontrolled gout) actively enrolling; top-line data expected H2 2027.","Company expects cash balance ~$50M by April 2026 with no outstanding debt or warrants.","No specific FY2025 financial numbers disclosed in the press release; focus on business and regulatory milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-029846","json":"https://secwatch.observer/filing/0001104659-26-029846.json","markdown":"https://secwatch.observer/filing/0001104659-26-029846.md","text":"https://secwatch.observer/filing/0001104659-26-029846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/0001104659-26-029846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/plx-20260318x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:48:45.575124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2738aa6133715c9338c61a01b47ae0c59383abd3","claim":"Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.","evidence_excerpt":"On March 18, 2026, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025 and provided a business and clinical update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/0001104659-26-029846-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}